Iron Replacement Therapy Triferic AVNU Now Available
Triferic is an iron maintenance therapy that delivers between 5 to 7mg of iron with every hemodialysis treatment and maintains hemoglobin without increasing ferritin.
Triferic is an iron maintenance therapy that delivers between 5 to 7mg of iron with every hemodialysis treatment and maintains hemoglobin without increasing ferritin.
In the CREDENCE trial, patients receiving canagliflozin had reduced risks of initiating iron therapy and erythropoiesis-stimulating agents compared with patients receiving placebo.
The Agency announced that additional clarification of clinical data was needed prior to completing the review.
The comparative study aimed to analyze AEs as well as estimate the associated medical costs for 4 IV iron preparations.
Pegcetacoplan is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that inhibits the complement cascade centrally at C3 and C3b.
Sutimlimab is an investigational monoclonal antibody designed to stop hemolysis by selectively inhibiting C1s in the classical complement pathway.
The FDA has approved a new 100mg/mL formulation of Ultomiris® (ravulizumab-cwvz; Alexion Pharmaceuticals) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and for atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and pediatric patients.
Deferiprone is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy.
Despite favorable efficacy data, the HIF-PHI failed to demonstrate noninferiority to the ESA in patients with CKD with respect to the primary MACE safety endpoint.